The Week of June 3 in Review
The week of June 3 in review, featuring content on crizotinib in NSCLC, an FDA approval, novel agents for the treatment of prostate cancer, and more.
Crizotinib Superior to Chemotherapy for Advanced ALK-Positive NSCLC
Crizotinib demonstrated superiority to chemotherapy for the treatment of previously treated, advanced non-small cell lung cancer (NSCLC) with ALK rearrangement in a trial published online by The New England Journal of Medicine on June 1.
Dr. Schuchter Gives an Overview of the Treatment of Melanoma
Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, gives an overview of the treatment of advanced melanoma at the 2013 ASCO Annual Meeting.
Lenalidomide Approved by the FDA for the Treatment of Mantle Cell Lymphoma
The immunomodulatory agent lenalidomide (Revlimid) has been approved by the FDA to treat patients with mantle cell lymphoma (MCL) who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.
Dr. Neal D. Shore on the Approval of Radium-223
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, comments on the impact of the approval of radium-223 for bone metastases from prostate cancer.
Case-Based Discussion: Integrating Novel Agents Into the Treatment of Prostate Cancer
In the wake of the approval of several novel treatments for prostate cancerincluding antiandrogens enzalutamide and abiraterone and immunotherapy sipuleucel-T, physicians must now focus on how best to integrate new therapies into the treatment of patients with prostate cancer.
Bundled Payment: Practice Savior or Killer?
The new “in” term among those looking to lower the cost of healthcare is “bundled payment” (BP). Although there is still disagreement about what it means, the bundling of payments revolves around oncologists being paid a set fee for managing their patients’ care.
Electra D. Paskett, PhD, on Vinegar as a Cervical Cancer Screening Tool
Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, describes the use of vinegar (acetic acid) as a cervical cancer screening tool.
Improving the Transition From Inpatient to Outpatient Care in Oncology
November 27th 2024A recent Targeted Oncology survey explores the challenges and best practices in transitioning patients with cancer from inpatient to outpatient care, featuring insights from Cristina Gasparetto, MD, on improving these processes.
Read More
Phase 1b/2 Study of BXQ-350 in Metastatic Colorectal Cancer Completes Enrollment
November 27th 2024Enrollment has been completed for the phase 1b/2 ASIST study that is evaluating BXQ-350 in combination with standard-of-care treatments in patients with newly diagnosed metastatic colorectal cancer.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
